What Is the GMP Regulatory Harmonization Hotline
Since 2026, Korea's Ministry of Food and Drug Safety and the Korea Pharmaceutical and Bio-Pharma Manufacturers Association have jointly operated a GMP Regulatory Harmonization Hotline. As global GMP (Good Manufacturing Practice) requirements from regulators like the US FDA and EU EMA continue to shift, this channel gives domestic manufacturers a standing point of contact to raise questions and receive authoritative guidance in real time.
The hotline was launched to address a persistent problem: delayed on-the-ground responses to changing global standards. Individual companies had been relying on their own interpretations of documentation systems and validation requirements ahead of overseas inspections, which led to inconsistent compliance levels across the industry and recurring inspection findings for similar issues. The hotline aims to close this gap and align the industry's overall response standard.
Biocide Regulation Takes Effect and Its Impact on GMP Operations
The issue drawing the most attention alongside the hotline's launch is biocide product regulation. With the grace period ending in July 2026, most of the disinfectants and antimicrobial agents used on manufacturing floors now fall under the Ministry of Environment's biocidal product approval system.
The core conflict is with GMP validation requirements. Under GMP, a validated disinfectant cannot simply be swapped out — switching to a new product requires a full re-validation cycle, including microbiological efficacy testing, cleaning validation, and residue testing. Companies are now caught between two regulatory demands: they can neither keep using an unapproved existing disinfectant nor immediately switch to an approved substitute without lengthy re-validation. Industry estimates put the validation timeline for replacing even a single disinfectant at a minimum of three to six months — a significant burden for small and mid-sized pharma and bio companies with limited quality assurance staff and budget.
In response to industry feedback, the government and trade associations are discussing temporary grace measures and phased implementation options. However, many of the final implementation details have yet to be confirmed, so companies are better served by proactively building a response strategy rather than waiting for the final announcement.
Response Strategies for Small and Mid-Sized Pharma and Bio Companies
1. Use the GMP hotline proactively
Rather than relying solely on internal judgment for questions about disinfectant replacement or inspection readiness, companies should secure authoritative interpretations through the hotline in advance. Documenting these Q&A exchanges also provides useful supporting evidence during future inspections.
2. Build a disinfectant replacement roadmap
Companies should conduct a full inventory of disinfectants and antimicrobial agents used across their manufacturing processes and classify which ones fall under biocide approval requirements. From there, pre-selecting candidate replacement products and working backward to set a validation schedule allows companies to avoid scrambling as the grace period deadline approaches.
3. Partner with documentation and regulatory affairs experts
Overhauling GMP documentation systems and building validation plans is demanding in both time and expertise for internal teams to handle alone. KITIM (Korea Institute of Technology Innovation Management) supports small and mid-sized pharma and bio companies with GMP documentation system overhauls, validation master plan development, and regulatory affairs advisory — helping them respond efficiently to regulatory change.
In a period of rapid regulatory change, proactive preparation is the most reliable way to reduce both inspection risk and production disruption at the same time. If you need support with GMP validation strategy or biocide regulation response consulting, please contact KITIM's expert consultants.